Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO

The increasing complexity of emerging technologies needed for drug discovery demands bigger players who can bring them together on one platform to optimize for best possible results. Evotec AG says that megatrend lies behind its purchase of the CRO Aptuit, creating a "one-stop-shop" for external innovation.

"The rationale behind this acquisition is to give everyone the option to go much faster on a very clear path to IND [Investigational New Drug] filing and for manufacturing. That makes processes more efficient, and ultimately cuts costs and time spent for both small and large drug companies, as well as for our own internal discovery efforts